Hengrui Pharmaceutical (600276.SH): Application for marketing licensing of Ruikang Luzetolatamab for injection was accepted

Zhitongcaijing · 2d ago

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. received the “Notice of Acceptance” issued by the State Drug Administration, and the company's drug marketing license application for injectable Ruikang Luzetolutamab (SHR-A2009 for injections) was accepted by the State Drug Administration.

Proposed Indications (or Functional Indications): This product is used for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) progressing positive EGFR gene mutations after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI).